Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

0.36USD
14 Nov 2018
Change (% chg)

-- (--)
Prev Close
$0.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
740,241
52-wk High
$2.80
52-wk Low
$0.35

Latest Key Developments (Source: Significant Developments)

Synergy Pharmaceuticals Q3 Loss Per Share $0.14
Thursday, 8 Nov 2018 05:00pm EST 

Nov 8 (Reuters) - Synergy Pharmaceuticals Inc ::SYNERGY PHARMACEUTICALS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE.Q3 LOSS PER SHARE $0.14.Q3 EARNINGS PER SHARE VIEW $-0.14 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 SALES $42 MILLION TO $47 MILLION.CONTINUING DISCUSSIONS WITH CRG AND HAS TWICE RECEIVED TEMPORARY WAIVERS ON MINIMUM MARKET CAP COVENANT.CURRENTLY PURSUING ALTERNATIVES THAT BETTER ALIGN WITH ITS BUSINESS.COULD DEFAULT UNDER TERM LOAN AGREEMENT AND MAY HAVE TO PURSUE OR OTHERWISE ACCELERATE STRATEGIC ALTERNATIVES.STRATEGIC ALTERNATIVES TO BE PURSUED COULD INCLUDE POSSIBILITY OF SEEKING BANKRUPTCY PROTECTION.PROJECTING TRULANCE TOTAL NET SALES FOR 2018 TO BE BETWEEN $42.0 MILLION TO $47.0 MILLION.  Full Article

Synergy Pharmaceuticals Provides Business Update
Thursday, 25 Oct 2018 05:00pm EDT 

Oct 25 (Reuters) - Synergy Pharmaceuticals Inc ::SYNERGY PHARMACEUTICALS PROVIDES BUSINESS UPDATE.SEES FY 2018 SALES $42 MILLION TO $47 MILLION.TO DATE, OFFERS RECEIVED TO ACQUIRE SYNERGY HAVE BEEN SIGNIFICANTLY BELOW COMPANY'S CURRENT MARKET VALUE.HAS BEEN UNABLE TO CONSUMMATE ANY PARTNERSHIP OPPORTUNITIES.SEEKING TO RENEGOTIATE TERMS OF ITS TERM LOAN AGREEMENT WITH CRG SERVICING LLC.SYNERGY PHARMACEUTICALS - AT THIS TIME, DOES NOT BELIEVE WILL OBTAIN ANY OFFERS THAT ARE SIGNIFICANTLY HIGHER IN VALUE THAN THOSE RECEIVED TO DATE.DECIDED TO FOREGO DRAWING DOWN ON ANY ADDITIONAL AMOUNTS PURSUANT TO ITS TERM LOAN AGREEMENT.HAS BEEN UNABLE TO FURTHER AMEND AGREEMENT WITH RESPECT TO FINANCIAL AND REVENUE COVENANTS.IS CONTINUING DISCUSSIONS WITH CRG FOR COVENANT RELIEF.SYNERGY PHARMACEUTICALS - TRULANCE UPTAKE IN 2018 SLOWER THAN EXPECTED DUE TO HIGHLY COMPETITIVE MARKET ACCESS ENVIRONMENT.SYNERGY PHARMACEUTICALS - IF CO DEFAULTS UNDER TERM LOAN , MAY HAVE TO ACCELERATE ALTERNATIVES, INCLUDING POSSIBILITY OF SEEKING BANKRUPTCY PROTECTION.TRULANCE UPTAKE IN 2018 HAS BEEN SLOWER THAN ANTICIPATED ALSO DUE TO SLOWER THAN ANTICIPATED OVERALL MARKET GROWTH.PROJECTING TRULANCE TOTAL NET SALES FOR 2018 TO BE BETWEEN $42.0 MILLION TO $47.0 MILLION.  Full Article

Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results
Tuesday, 7 Aug 2018 05:00pm EDT 

Aug 7 (Reuters) - Synergy Pharmaceuticals Inc ::SYNERGY PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE.Q2 LOSS PER SHARE $0.12.Q2 EARNINGS PER SHARE VIEW $-0.15 -- THOMSON REUTERS I/B/E/S.QTRLY NET SALES $12.3 MILLION VERSUS $2.3 MILLION.Q2 REVENUE VIEW $12.0 MILLION -- THOMSON REUTERS I/B/E/S.SECURES EX-US LICENSING DEAL FOR TRULANCE IN CHINA.  Full Article

Synergy Pharmaceuticals Announces License Agreement With Luoxin Pharmaceutical Group
Tuesday, 7 Aug 2018 06:00am EDT 

Aug 7 (Reuters) - Synergy Pharmaceuticals Inc ::SYNERGY PHARMACEUTICALS ANNOUNCES LICENSE AGREEMENT WITH LUOXIN PHARMACEUTICAL GROUP FOR TRULANCE® (PLECANATIDE) IN CHINA.SYNERGY PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, SYNERGY WILL RECEIVE AN UPFRONT PAYMENT OF $12 MILLION.SYNERGY - ALSO ELIGIBLE, IF SOME MILESTONES MET, TO GET ADDITIONAL PAYMENTS OF UP TO $56 MILLION.SYNERGY PHARMACEUTICALS INC - ELIGIBLE TO RECEIVE TIERED ROYALTY PAYMENTS ON AGGREGATE NET SALES.  Full Article

CVI Investments reports a 7.9 pct passive stake in Synergy Pharmaceuticals as of Nov 13, 2017
Wednesday, 22 Nov 2017 05:00pm EST 

Nov 22 (Reuters) - Synergy Pharmaceuticals Inc :CVI Investments Inc reports a 7.9 percent passive stake in Synergy Pharmaceuticals Inc as of November 13, 2017 - SEC Filing‍​.  Full Article

Synergy Pharma announces pricing of offering of common stock and warrants
Monday, 13 Nov 2017 09:27am EST 

Nov 13 (Reuters) - Synergy Pharmaceuticals Inc :Synergy Pharmaceuticals announces pricing of offering of common stock and warrants.Synergy Pharmaceuticals - ‍pricing of offering of 21.7 million shares with accompanying warrants at combined price to public of $2.58/share and warrant​.  Full Article

Synergy Pharmaceuticals posts Q3 loss per share $0.22
Thursday, 9 Nov 2017 04:00pm EST 

Nov 9 (Reuters) - Synergy Pharmaceuticals Inc :Synergy Pharmaceuticals reports third quarter 2017 financial results and business update.Q3 loss per share $0.22.Q3 sales $5.0 million versus I/B/E/S view $4.5 million.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Synergy Pharmaceuticals Inc - ‍cash and cash equivalents were about $117.8 million at end of quarter​.  Full Article

Synergy Pharma's bowel drug succeeds in first phase 3 trial
Friday, 9 Dec 2016 08:41am EST 

Synergy Pharmaceuticals Inc : Synergy Pharmaceuticals announces positive results in first phase 3 trial of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C) . Synergy Pharmaceuticals Inc - preliminary analysis of data indicates that both plecanatide 3 mg and 6 mg doses met study's primary endpoint . Synergy Pharmaceuticals -pending approval in CIC indication, co plans to file new drug application supplement with clinical data for plecanatide in IBS-C in q1 2017 . Synergy Pharmaceuticals Inc - four patients in trial (0.4%) experienced serious adverse events . Synergy Pharma- common adverse event was diarrhea that was in 3.2% of patients in 3 mg,3.7% patients in 6 mg dose groups versus 1.3% placebo-treated patients .Synergy Pharmaceuticals announces positive results in first phase 3 trial of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C).  Full Article